Lynch syndrome arises from inherited mutations in DNA mismatch repair genes, leaving affected individuals with a significantly elevated lifetime risk of colorectal cancer as well as several other malignancies. For this population, prevention is not an abstract concept but a daily reality shaped by intensive surveillance programs, genetic counseling, and difficult decisions about risk-reducing interventions. The scientific case for aspirin in this context has been building for years. The landmark CAPP2 study demonstrated that acetylsalicylic acid can significantly reduce the long-term risk of colorectal cancer in people with Lynch syndrome, using a comparatively high daily dose of 600 milligrams. That evidence positioned aspirin as one of the few chemopreventive agents with robust data in a hereditary cancer setting, offering a low-cost, widely accessible complement to regular colonoscopic surveillance.

The picture grew even more promising with the recently published international CaPP3 study, which suggests that a much lower dose of 100 milligrams daily could deliver a similar cancer-preventive effect while causing fewer side effects, and in particular fewer bleeding complications, which have long been the principal concern associated with long-term aspirin use. The prospect of a practical, better-tolerated regimen is significant for a group that must weigh preventive benefit against decades of continuous medication. Dr. Robert Hüneburg, corresponding author of the new study and a senior physician at Medical Clinic I at the UKB who also conducts research at the University of Bonn, urged measured interpretation of the dose comparison. Since the statistical criteria for formal equivalence between the two studies were not met in all analyses, he noted, the results should still be interpreted with some caution. However, he added, the CaPP3 findings suggest that 100 milligrams daily could be a practical and better-tolerated option for many patients.

Against this backdrop of evolving evidence, the Bonn team set out to measure how much of the science has actually reached clinical practice. The LYNX survey enrolled 539 people with Lynch syndrome from across Germany and was designed before the publication of the CaPP3 results, then conducted between December 2025 and February 2026. That timing matters for interpretation: the responses reflect the use of acetylsalicylic acid based on the scientific evidence available at the time of the survey, primarily the higher-dose CAPP2 findings. Hüneburg emphasized that future studies must show whether the new findings on lower dosages will contribute to acetylsalicylic acid being used more frequently for cancer prevention. In other words, the survey captures a snapshot of care under the old evidence regime, and the lower-dose data may yet shift the calculus for both physicians and patients.

What the survey revealed was not ignorance or apathy but a paradox. Awareness of established prevention measures among respondents was exceptionally high: about 97 percent were familiar with the specific screening recommendations for Lynch syndrome, and nearly all undergo regular colonoscopies. Adherence to surveillance, the cornerstone of Lynch syndrome care, is therefore excellent. Yet when it came to aspirin, the numbers collapsed. Only 10.4 percent of respondents reported currently taking acetylsalicylic acid, and just 6.9 percent of the entire group specifically used it for cancer prevention in the context of Lynch syndrome. For a population in which a well-studied, inexpensive preventive agent exists, those figures represent a profound gap between evidence and everyday care.

The reasons patients gave for avoiding aspirin were revealing. According to Dr. Anne-Sophie Layritz, co-first author of the study and an assistant physician at Medical Clinic I at the UKB, the main reasons cited were a lack of prior engagement with the topic, concerns about side effects, and uncertainty regarding the scientific evidence. Each of these barriers points to a different failure point in the care pathway. A lack of engagement suggests that the topic is simply not being raised consistently during counseling appointments. Concerns about side effects reflect legitimate worries about gastrointestinal bleeding that the lower-dose CaPP3 data may help address. Uncertainty about the evidence indicates that patients perceive the scientific picture as unsettled, a perception that clearer, more structured communication from care teams could correct. None of these barriers suggests resistance to prevention itself.

Indeed, the same survey documented remarkable enthusiasm for novel preventive approaches. About three-quarters of respondents could, in principle, imagine participating in a study on a preventive mRNA cancer vaccine, a technology that has moved from pandemic fame to the frontier of oncology. After receiving additional information about the concept, that proportion rose to about 80 percent. More strikingly, more than 92 percent stated that they would want to receive such a vaccine if it were approved in the future. A majority of participants also accepted the possibility of being assigned to a placebo group in such trials and the inherent risk of side effects, both of which are common sticking points in clinical trial recruitment. Nicola Reents, co-first author of the study representing SemiColon, said these results show just how great the interest is among those affected in innovative prevention options and in actively participating in research.

Taken together, the LYNX findings do not indicate any fundamental reluctance toward cancer prevention among people with Lynch syndrome. Instead, the authors describe a significant implementation gap between scientific evidence, medical counseling, and actual application. The community is demonstrably willing to embrace prevention, whether through established tools like colonoscopy or through future innovations like mRNA vaccines, but the translation of aspirin data into routine counseling has lagged. According to the authors, early, understandable, and structured information, together with an individualized assessment of benefits and risks, is crucial to closing that gap. As the lower-dose evidence matures, the window is open for care teams to revisit how chemoprevention is discussed, ensuring that patients receive balanced, up-to-date guidance rather than leaving aspirin’s potential benefits unexamined.

The collaborative design of the study itself offers a model for how such gaps might be bridged. Support from the centers of the German Consortium Familial Colorectal Cancer and the partnership with the self-help organization SemiColon were of central importance to the project, allowing the researchers to reach many affected individuals and to contextualize both the research questions and the results from the patients’ perspective. Reents of SemiColon served as a co-first author of the publication, an unusual and telling arrangement that embedded the patient voice directly into the research process. Hüneburg emphasized that the project is a very good example of research that is conducted not just about, but together with, those affected. For a condition in which lifelong engagement with prevention determines outcomes, that participatory approach may prove as consequential as any single clinical finding, pointing toward a future in which the evidence, the counseling, and the patient’s own informed decision finally align.

Subject of Research: Aspirin chemoprevention uptake among people with Lynch syndrome

Article Title: Aspirin rarely used for colorectal cancer prevention

Article References: Aspirin rarely used for colorectal cancer prevention. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Lynch syndrome, colorectal cancer, aspirin, chemoprevention, CAPP2 study, CaPP3 study, cancer prevention, mRNA cancer vaccine, implementation gap, genetic predisposition, University Hospital Bonn, patient survey